Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nina D. Wagner-Johnston, Ajay K. Gopal, Brad S. Kahl, Sven De Vos, Stephen J. Schuster, Wojciech Jurczak, Ian Flinn, Christopher Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, Andre Goy, Andrew John Davies, Pier Luigi Zinzani, Martin H. Dreyling, Lynne I. Wagner, Bess Sorensen, Wayne Russell Godfrey, Gilles A. Salles
Institutions: Washington University in St. Louis, University of Washington, Fred Hutch Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of California, Los Angeles, Los Angeles Medical Center, Abramson Cancer Center, University of Pennsylvania, Jagiellonian University, Sarah Cannon, Emory University, Weill Cornell Medicine, University Hospital Ulm, The Ohio State University, Hackensack University Medical Center, University of Southampton, University of Bologna, München Klinik, Ludwig-Maximilians-Universität München, Northwestern University, Gilead Sciences (United States), Hôpital Lyon Sud
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2598092333